Session Information
Date: Tuesday, October 23, 2018
Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Methods: GO-VIBRANT is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled trial. Adults with active PsA who were biologic-naïve (n=480; aged ≥18 years) were randomized to IV golimumab 2 mg/kg at Weeks 0 and 4 and every 8 weeks thereafter (n=241), or placebo at Weeks 0, 4, 12, and 20 with crossover to IV golimumab at Week 24 (n=239). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and HRQoL and physical function were measured by the Short-Form 36 (SF-36) and Health Assessment Questionnaire Disability Index (HAQ-DI). ANCOVA, T-test, CMH test, and Chi-square test were used for various analyses.
|
||||
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
||||
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*p-value is based on Chi-Square test controlling for treatment |
|||
|
|||
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*p-value is based on t-test controlling for baseline value of quality of life parameters. All variables are based on observed score, **estimate represents the average impact of having |
To cite this abstract in AMA style:
Kavanaugh A, Husni ME, Chan EKH, Harrison DD, Kim L, Lo KH, Hsia EC, Han C. Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/fatigue-in-psoriatic-arthritis-patients-treated-with-intravenous-golimumab-early-improvement-is-associated-with-week-24-outcomes-in-acr-20-50-and-health-related-quality-of-life/. Accessed .« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/fatigue-in-psoriatic-arthritis-patients-treated-with-intravenous-golimumab-early-improvement-is-associated-with-week-24-outcomes-in-acr-20-50-and-health-related-quality-of-life/